- Home
- RPD vs TSHA Comparison
RPD vs TSHA Comparison
Compare RPD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPD | TSHA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RPD | TSHA |
|---|---|---|
| Price | $15.40 | $5.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 21 | 9 |
| Target Price | ★ $24.00 | $10.22 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 02-11-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $858,667,000.00 | $6,310,000.00 |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | $44.24 | ★ N/A |
| Revenue Growth | ★ 3.08 | N/A |
| 52 Week Low | $13.21 | $1.05 |
| 52 Week High | $41.38 | $6.02 |
Technical Indicators
Market Signals| Indicator | RPD | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 61.09 |
| Support Level | $15.06 | $5.37 |
| Resistance Level | $15.90 | $6.02 |
| Average True Range (ATR) | 0.46 | 0.30 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 15.93 | 77.72 |
Price Performance
Historical ComparisonAbout RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.